Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
The Market Has Spoken: BridgeLink Surpasses 10,000 Downloads, Solidifying Status as the Global Standard for Open-Source Health Interoperability27.1.2026 18:35:00 CET | Press release
MONTGOMERY, AL / ACCESS Newswire / January 27, 2026 / Innovar Healthcare today announced that BridgeLink, the open-source integration engine, has surpassed 10,000 enterprise downloads, a milestone that signals a decisive shift in the healthcare IT landscape. Following the market shift toward restrictive proprietary licensing for the industry's legacy engine, the healthcare community has decisively moved to BridgeLink as the premier open-source replacement. This rapid adoption-achieved in less than a year since its March 2025 launch-confirms that healthcare organizations are prioritizing strategic resilience and technical transparency over vendor lock-in. BridgeLink is no longer just an alternative; it has become the operational standard for hospitals, Digital Health, Health Information Exchanges (HIEs), and laboratories worldwide seeking to secure their interoperability infrastructure. "The volume of downloads we are seeing represents a 'Great Migration' in health tech," said Loyd Bitt
Symetrix Unveils Cognio: The Next-Generation Audio, Video, and Control Platform27.1.2026 14:15:00 CET | Press release
With breakthrough distributed architecture and wire-free design workflows, Cognio redefines how AV systems are designed, deployed, and operated; see it for the first time at ISE 2026 SEATTLE, WA / ACCESS Newswire / January 27, 2026 / Symetrix, a global leader in high-performance AV processing, control, and monitoring solutions, today announced the launch of Cognio™, a brand-new software-driven Audio, Video, and Control (AVC) ecosystem designed to dramatically simplify system design, accelerate deployment, and deliver more flexible, scalable AV experiences. Cognio will make its official public debut at Integrated Systems Europe (ISE) 2026 in Barcelona, where attendees can experience an entirely new approach to deploying Audio, Video, and Control solutions at the Symetrix booth (5M390). Cognio represents a fundamental rethinking of how AV systems are built, combining distributed intelligence with code-free control into a single platform powered by DesignOps, the patented software that un
U.S. Polo Assn. Celebrates a Landmark Debut as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz27.1.2026 13:00:00 CET | Press release
Standing Rock Claims Victory Over Flexjet in a Thrilling Final Showdown WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 27, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), celebrated its inaugural year as the Official Jersey and Apparel Partner of the 41st Snow Polo World Cup St. Moritz. The legendary three-day competition and record-breaking lifestyle event took place on the iconic frozen Lake St. Moritz in Switzerland's Engadin Valley and featured world-class competition, alpine elegance, fan activations, VIP experiences, and global sport celebration. More than 2,400 tons of infrastructure were installed directly onto the frozen lake of St. Moritz for this one-of-a-kind event. After two days and eight games of preliminaries, on Sunday, Jan. 25, Standing Rock prevailed over Flexjet in a close 6 - 4.5 victory.1. The intensity was high in the final Snow Polo World Cup game, with Standing Rock ultimately prevaili
AM Positions for Next Phase of Global Growth: Kelly McAndrew to Chairman; Dave Watrous to CEO27.1.2026 07:00:00 CET | Press release
AUSTIN, TX / ACCESS Newswire / January 27, 2026 / For over 21 years, Kelly McAndrew has served as Chief Executive Officer (CEO), playing a pivotal role in shaping AM Technical Solutions (AM) culture and strategic direction, enabling exceptional results. Kelly now transitions into the role of Chairman of the Board. As Chairman, Kelly will focus on investments and partnerships to further enhance the company's solution offerings. Dave Watrous will succeed Kelly as Chief Executive Officer. AM has worked closely with Dave for more than six years in the roles of customer and partner. His faith, integrity, leadership qualities, and strong industry expertise make him the ideal choice for this role. With a distinguished 30-year career in High-Technology industries, Dave brings extensive capabilities in delivering multi-billion-dollar Engineering, Procurement, Construction, Commissioning, and Validation projects worldwide. As CEO, Dave will focus on leading growth, accelerating opportunities, en
Richter Extends Its Support to Africa - The First Year of the House of Hope in Bamako in Numbers26.1.2026 14:00:00 CET | Press release
The First Year of the House of Hope in Bamako in Numbers BUDAPEST, HU / ACCESS Newswire / January 26, 2026 / Nearly one year has passed since the House of Hope centre, established by Richter Gedeon Plc., began providing shelter and comprehensive support to women in Bamako. During this period, almost 120 women and girls have benefited from healthcare, legal aid and education. Interest in the centre remains strong, with new women continuously joining the programme. In the coming years, the initiative aims to reach several hundred vulnerable women across different regions of Mali. Why Was the House of Hope Established? The centre was created through the collaboration of Richter Gedeon Plc. (Richter), the Hungary-based Close to Africa Foundation, and the local Sini Sanuman Foundation. Its mission is to provide safety and professional support to women fleeing violence and abuse through gynaecological care, psychological and legal counselling, and educational programmes. The building was des
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom